PURPOSE: Chronic lymphocytic leukemia (CLL) is a heterogeneous disease with cytogenetic aberrations that are still considered the gold standard of prognostic factors. However, heterogeneity remains within each cytogenetic group, especially in patients with concomitant cytogenetic aberrations. METHODS: A panel of DNA probes was used to detect cytogenetic aberrations, including RB1/D13S25 at 13q14, ATM at 11q22, TP53 at 17p13, CEP12 and IGH translocation at 14q32, by fluorescence in situ hybridization. A comprehensive method integrating the number of cytogenetic aberrations and intratumoral genetic heterogeneity was used to analyze the prognosis for patients with concomitant aberrations. RESULTS: Within the conventional favorable or neutral prognostic groups (i.e., with del 13q, trisomy 12, and/or t(14q32)), the coincidence of these three aberrations worsened survival in terms of time to first therapy, progression-free survival, and overall survival. However, within the conventional unfavorable prognostic group (i.e., del 11q or del 17p), patients with a minor unfavorable clone had an unexpected survival advantage compared with patients with a major unfavorable clone. A new cytogenetic prognostic system that integrates the number of cytogenetic aberrations and intratumoral genetic subclones was more precise than the conventional system. CONCLUSION: The number of cytogenetic aberrations and the size of intratumoral genetic subclones should be comprehensively considered to determine the prognosis for CLL.Genet Med 19 2, 182-191.
PURPOSE: Chronic lymphocytic leukemia (CLL) is a heterogeneous disease with cytogenetic aberrations that are still considered the gold standard of prognostic factors. However, heterogeneity remains within each cytogenetic group, especially in patients with concomitant cytogenetic aberrations. METHODS: A panel of DNA probes was used to detect cytogenetic aberrations, including RB1/D13S25 at 13q14, ATM at 11q22, TP53 at 17p13, CEP12 and IGH translocation at 14q32, by fluorescence in situ hybridization. A comprehensive method integrating the number of cytogenetic aberrations and intratumoral genetic heterogeneity was used to analyze the prognosis for patients with concomitant aberrations. RESULTS: Within the conventional favorable or neutral prognostic groups (i.e., with del 13q, trisomy 12, and/or t(14q32)), the coincidence of these three aberrations worsened survival in terms of time to first therapy, progression-free survival, and overall survival. However, within the conventional unfavorable prognostic group (i.e., del 11q or del 17p), patients with a minor unfavorable clone had an unexpected survival advantage compared with patients with a major unfavorable clone. A new cytogenetic prognostic system that integrates the number of cytogenetic aberrations and intratumoral genetic subclones was more precise than the conventional system. CONCLUSION: The number of cytogenetic aberrations and the size of intratumoral genetic subclones should be comprehensively considered to determine the prognosis for CLL.Genet Med 19 2, 182-191.
Authors: K Tamura; H Sawada; Y Izumi; T Fukuda; A Utsunomiya; S Ikeda; N Uike; J Tsukada; F Kawano; T Shibuya; H Gondo; S Okamura; J Suzumiya Journal: Eur J Haematol Date: 2001-09 Impact factor: 2.997
Authors: Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillaume Dighiero; Hartmut Döhner; Peter Hillmen; Michael J Keating; Emili Montserrat; Kanti R Rai; Thomas J Kipps Journal: Blood Date: 2008-01-23 Impact factor: 22.113
Authors: Patricia T Greipp; Stephanie A Smoley; David S Viswanatha; Lori S Frederick; Kari G Rabe; Ruchi G Sharma; Susan L Slager; Daniel L Van Dyke; Tait D Shanafelt; Renee C Tschumper; Clive S Zent Journal: Br J Haematol Date: 2013-08-27 Impact factor: 6.998
Authors: Dan A Landau; Eugen Tausch; Amaro N Taylor-Weiner; Chip Stewart; Johannes G Reiter; Jasmin Bahlo; Sandra Kluth; Ivana Bozic; Mike Lawrence; Sebastian Böttcher; Scott L Carter; Kristian Cibulskis; Daniel Mertens; Carrie L Sougnez; Mara Rosenberg; Julian M Hess; Jennifer Edelmann; Sabrina Kless; Michael Kneba; Matthias Ritgen; Anna Fink; Kirsten Fischer; Stacey Gabriel; Eric S Lander; Martin A Nowak; Hartmut Döhner; Michael Hallek; Donna Neuberg; Gad Getz; Stephan Stilgenbauer; Catherine J Wu Journal: Nature Date: 2015-10-14 Impact factor: 49.962
Authors: J Malcikova; K Stano-Kozubik; B Tichy; B Kantorova; S Pavlova; N Tom; L Radova; J Smardova; F Pardy; M Doubek; Y Brychtova; M Mraz; K Plevova; E Diviskova; A Oltova; J Mayer; S Pospisilova; M Trbusek Journal: Leukemia Date: 2014-10-28 Impact factor: 11.528
Authors: Daniel L Van Dyke; Lillian Werner; Laura Z Rassenti; Donna Neuberg; Emanuella Ghia; Nyla A Heerema; Paola Dal Cin; Marie Dell Aquila; Chandrika Sreekantaiah; Andrew W Greaves; Thomas J Kipps; Neil E Kay Journal: Br J Haematol Date: 2016-02-05 Impact factor: 6.998
Authors: Seila Lorenzo-Herrero; Christian Sordo-Bahamonde; Gabriel Bretones; Ángel R Payer; Ana P González-Rodríguez; Esther González-García; Jhudit Pérez-Escuredo; Mónica Villa-Álvarez; Luz-Elena Núñez; Francisco Morís; Segundo Gonzalez; Alejandro López-Soto Journal: Front Immunol Date: 2019-10-18 Impact factor: 7.561